KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EPS (Basic) (2016 - 2025)

Sarepta Therapeutics has reported EPS (Basic) over the past 15 years, most recently at -$3.93 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$3.93 for Q4 2025, down 338.18% from a year ago — trailing twelve months through Dec 2025 was -$7.02 (down 386.53% YoY), and the annual figure for FY2025 was -$7.13, down 388.66%.
  • EPS (Basic) for Q4 2025 was -$3.93 at Sarepta Therapeutics, down from -$0.5 in the prior quarter.
  • Over the last five years, EPS (Basic) for SRPT hit a ceiling of $2.01 in Q2 2025 and a floor of -$5.86 in Q1 2023.
  • Median EPS (Basic) over the past 5 years was -$0.81 (2021), compared with a mean of -$1.18.
  • Peak annual rise in EPS (Basic) hit 2771.43% in 2025, while the deepest fall reached 1310.53% in 2025.
  • Sarepta Therapeutics' EPS (Basic) stood at -$1.43 in 2021, then rose by 13.29% to -$1.24 in 2022, then skyrocketed by 161.29% to $0.76 in 2023, then surged by 117.11% to $1.65 in 2024, then plummeted by 338.18% to -$3.93 in 2025.
  • The last three reported values for EPS (Basic) were -$3.93 (Q4 2025), -$0.5 (Q3 2025), and $2.01 (Q2 2025) per Business Quant data.